Simvastatin Versus Ezetimibe

DOI Web Site 被引用文献15件
  • Ulf Landmesser
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Ferdinand Bahlmann
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Maja Mueller
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Stephan Spiekermann
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Nina Kirchhoff
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Svenja Schulz
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Costantina Manes
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Dieter Fischer
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Kirsten de Groot
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Danilo Fliser
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Günter Fauler
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Winfried März
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.
  • Helmut Drexler
    From Abteilung Kardiologie und Angiologie (U.L., M.M., S.S., N.K., S.S., C.M., D. Fischer, H.D.) and Abteilung Nephrologie (F.B., K.d.G., D. Fliser), Medizinische Hochschule Hannover, Hannover, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics (G.F., W.M.), Medical University of Graz, Graz, Austria.

書誌事項

タイトル別名
  • Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans

抄録

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Statins may exert important pleiotropic effects, ie, improve endothelial function, independently of their impact on LDL cholesterol. In humans, however, pleiotropic effects of statins have never been unequivocally demonstrated because prolonged statin treatment always results in reduced LDL cholesterol levels. We therefore tested the hypothesis that similar reductions in LDL cholesterol with simvastatin and ezetimibe, a novel cholesterol absorption inhibitor, result in different effects on endothelial function. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> Twenty patients with chronic heart failure were randomized to 4 weeks of simvastatin (10 mg/d) or ezetimibe (10 mg/d) treatment. Flow-dependent dilation (FDD) of the radial artery was determined by high-resolution ultrasound before and after intra-arterial vitamin C to determine the portion of FDD inhibited by radicals (ΔFDD-VC). Activity of extracellular superoxide dismutase, a major vascular antioxidant enzyme system, was determined after release from the endothelium by a heparin bolus injection. Endothelial progenitor cells were analyzed with an in vitro assay. Simvastatin and ezetimibe treatment reduced LDL cholesterol to a similar extent (15.6% versus 15.4%; <jats:italic>P</jats:italic> =NS), whereas changes in mevalonate, the product of HMG-CoA-reductase, differed between groups (Δmevalonate-simvastatin, −1.04±0.62 versus Δmevalonate-ezetimibe, 1.79±0.94 ng/mL; <jats:italic>P</jats:italic> <0.05 between groups). Importantly, FDD was markedly improved after simvastatin (10.5±0.6% versus 5.1±0.7%; <jats:italic>P</jats:italic> <0.01) but not after ezetimibe treatment (5.6±0.5% versus 5.8±0.6%; <jats:italic>P</jats:italic> =NS). ΔFDD-VC was substantially reduced after simvastatin but not after ezetimibe treatment. Extracellular superoxide dismutase activity was increased by >100% ( <jats:italic>P</jats:italic> <0.05) after simvastatin but not ezetimibe treatment. Simvastatin treatment increased the number of functionally active endothelial progenitor cells, whereas ezetimibe had no effect. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Four weeks of simvastatin treatment improves endothelial function independently of LDL cholesterol lowering, at least in part by reducing oxidant stress. Simvastatin may thereby exert important pleiotropic effects in humans. </jats:p>

収録刊行物

  • Circulation

    Circulation 111 (18), 2356-2363, 2005-05-10

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (15)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ